Kamada Ltd. (KMDA.TA) Completes Enrollment In U.S. Pivotal Clinical Trial With Kamrab As A Post-Exposure Treatment For Rabies
3/4/2014 10:06:44 AM
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB® as a post-exposure prophylaxis (PEP) for rabies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by